Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Planning for the future? Find effective ways to save for future goals and ensure you reach your financial aspirations.
17,671 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
As Verastem prepares for its 2025 earnings outlook, investors should focus on cash runway, collaboration milestones, ...
Kick back this weekend with 10 thoughtful weekend reads that bridge big ideas and real-world investing. Each piece of...
A fresh settlement involving Ticketmaster sparked a rally in Live Nation shares, signaling investor relief but stirri...
Investors are weighing the upside of autonomous trucking against cost, timing, and risk. This article breaks down the...
U.S. consumer prices rose modestly in February, keeping annual inflation at 2.4% with a 0.3% monthly gain. Analysts s...
In a closed briefing, the White House revealed that six days of fighting with Iran cost at least $11.3 billion, with ...
Not all tech stocks pay dividends, but a small group do. Here are two reliable picks that blend growth with income, p...
Kinsale Capital has faced headwinds, but the core business still shows quality underwriting. Here’s why I’m staying i...
Stellus Capital Investment Corp remains a high-yield option in private credit, yet recent earnings misses and a divid...
As 2025 earnings season hits, savvy investors need a clear playbook for cibus (cbus) 2025 earnings. This guide breaks...
Gemini Space Station stock dropped sharply after a downgrade spurred by profitability concerns and cautious guidance....